Normal Laboratory Values: Blood, Plasma, and Serum
| Test | Specimen | Conventional Units | SI Units |
|---|---|---|---|
Acetoacetate | Plasma | < 1 mg/dL | < 0.1 mmol/L |
Acetylcholinesterase (ACE), RBC | Blood | 26.7–49.2 U/g Hb | — |
Acid phosphatase | Serum | 0.5–5.5 U/L | 0–0.9 μkat/L |
Activated partial thromboplastin time (aPTT) | Plasma | 25–35 sec | — |
Adrenocorticotropic hormone (ACTH) | Serum | 9–52 pg/mL | 2–11 pmol/L |
Albumin | Serum | 3.5–5.5 g/dL | 35–55 g/L |
| Aldosterone: | |||
Standing | Serum | 7–20 ng/dL | 194–554 pmol/L |
Supine | Serum | 2–5 ng/dL | 55–138 pmol/L |
Alkaline phosphatase (ALP) | Serum | 36–92 U/L | 0.5–1.5 μkat/L |
Alpha1-antitrypsin (AAT) | Serum | 83–199 mg/dL | — |
Alpha fetoprotein (AFP) | Serum | 0–20 ng/dL | 0–20 pg/L |
δ-Aminolevulinic acid (ALA) | Serum | 15–23 μg/L | 1.14–1.75 μmol/L |
Aminotransferase, alanine (ALT) | Serum | 0–35 U/L | 0–0.58 pkat/L |
Aminotransferase, aspartate (AST) | Serum | 0–35 U/L | 0–0.58 pkat/L |
Ammonia | Plasma | 40–80 μg/dL | 23–47 μmol/L |
Amylase | Serum | 0–130 U/L | 0–2.17 μkat/L |
Antibodies to extractable nuclear antigen (AENA) | Serum | < 20.0 units | — |
Anti–cyclic citrullinated peptide (anti-CCP) antibodies | Serum | ≤ 5.0 units | — |
| Antidiuretic hormone (ADH; arginine vasopressin) | Plasma | < 1.7 pg/mL | < 1.57 pmol/L |
Anti–double-stranded DNA (dsDNA) antibodies, IgG | Serum | < 25 IU | — |
Antimitochondrial M2 antibodies | Serum | < 0.1 units | — |
Antineutrophil cytoplasmic antibodies (cANCA) | Serum | Negative | — |
Antinuclear antibodies (ANA) | Serum | ≤ 1.0 units | — |
Anti–smooth muscle antibodies (ASMA) titer | Serum | ≤ 1:80 | — |
Antistreptolysin O titer | Serum | < 150 units | — |
Antithyroid microsomal antibody titer | Serum | < 1:100 | — |
α1-Antitrypsin (AAT) | Serum | 83–199 mg/dL | 15.3–36.6 μmol/L |
| Apolipoproteins: | |||
A-I, females | Serum | 98–210 mg/dL | 0.98–2.1 g/L |
A-I, males | Serum | 88–180 mg/dL | 0.88–1.8 g/L |
B-100, females | Serum | 44–148 mg/dL | 0.44–1.48 g/L |
B-100, males | Serum | 55–151 mg/dL | 0.55–1.51 g/L |
Bicarbonate | Serum | 23–28 mEq/L | 23–28 mmol/L |
| Bilirubin: | |||
Direct | Serum | 0–0.3 mg/dL | 0–5.1 μmol/L |
Total | Serum | 0.3–1.2 mg/dL | 5.1–20.5 μmol/L |
| Blood volume: | |||
Plasma, females | Blood | 28–43 mL/kg body wt | 0.028–0.043 L/kg body wt |
Plasma, males | Blood | 25–44 mL/kg body wt | 0.025–0.044 L/kg body wt |
RBCs, females | Blood | 20–30 mL/kg body wt | 0.02–0.03 L/kg body wt |
RBCs, males | Blood | 25–35 mL/kg body wt | 0.025–0.035 L/kg body wt |
Brain (B-type) natriuretic peptide (BNP) | Plasma | < 100 pg/mL | — |
| Calcitonin, age ≥ 16 yr: | |||
Females | Serum | < 8 pg/mL | — |
Males | Serum | < 16 pg/mL | — |
Calcium | Serum | 9–10.5 mg/dL | 2.2–2.6 mmol/L |
| Cancer antigen (CA): | |||
CA 125 | Serum | < 35 U/mL | — |
CA 15-3 | Serum | < 30 U/mL | — |
Carbon dioxide (CO2) content | Serum | 23–28 mEq/L | 23–28 mmol/L |
| Carbon dioxide partial pressure (PCO2) | Blood | 35–45 mm Hg | — |
Carboxyhemoglobin | Plasma | 0.5–5% | — |
Carcinoembryonic antigen (CEA) | Serum | < 2 ng/mL | < 2 μg/L |
Carotene | Serum | 75–300 μg/L | 1.4–5.6 μmol/L |
CD4:CD8 ratio | Blood | 1–4 | — |
CD4+ T-cell count | Blood | 640–1175/μL | 0.64–1.18 x 109/L |
CD8+ T-cell count | Blood | 335–875/μL | 0.34–0.88 x 109/L |
Ceruloplasmin | Serum | 25–43 mg/dL | 250–430 mg/L |
Chloride | Serum | 98–106 mEq/L | 98–106 mmol/L |
| Cholesterol, desirable level: | |||
High-density lipoprotein (HDL-C) | Plasma | ≥ 40 mg/dL | ≥ 1.04 mmol/L |
Low-density lipoprotein (LDL-C) | Plasma | ≤ 130 mg/dL | ≤ 3.36 mmol/L |
Total (TC) | Plasma | 150–199 mg/dL | 3.88–5.15 mmol/L |
| Coagulation factors: | |||
Factor I | Plasma | 150–300 mg/dL | 1.5–3.5 g/L |
Factor II | Plasma | 60–150% of normal | — |
Factor IX | Plasma | 60–150% of normal | — |
Factor V | Plasma | 60–150% of normal | — |
Factor VII | Plasma | 60–150% of normal | — |
Factor VIII | Plasma | 60–150% of normal | — |
Factor X | Plasma | 60–150% of normal | — |
Factor XI | Plasma | 60–150% of normal | — |
Factor XII | Plasma | 60–150% of normal | — |
| Complement: | |||
C3 | Serum | 55–120 mg/dL | 0.55–1.20 g/L |
C4 | Serum | 20–59 mg/dL | 0.20–0.59 g/L |
Total | Serum | 37–55 U/mL | 37–55 kU/L |
Copper | Serum | 70–155 μg/L | 11–24.3 μmol/L |
| Cortisol: | |||
1 h after cosyntropin | Serum | > 18 μg/dL and usually ≥ 8 μg/dL above baseline | > 498 nmol/L and usually ≥ 221 nmol/L above baseline |
At 5 pm | Serum | 3–13 μg/dL | 83–359 nmol/L |
At 8 am | Serum | 8–20 μg/dL | 251–552 nmol/L |
After overnight suppression test | Serum | < 5 μg/dL | < 138 nmol/L |
C-peptide | Serum | 0.9–4.3 ng/mL | 297–1419 pmol/L |
C-reactive protein (CRP) | Serum | < 0.5 mg/dL | < 0.005 g/L |
C-reactive protein, highly sensitive (hsCRP) | Serum | < 1.1 mg/L | < 0.0011 g/L |
Creatine kinase (CK) | Serum | 30–170 U/L | 0.5–2.83 μkat/L |
Creatinine | Serum | 0.7–1.3 mg/dL | 61.9–115 μmol/L |
d-Dimer | Plasma | ≤ 300 ng/mL | ≤ 300 μg/L |
| Dehydroepiandrosterone sulfate (DHEA-S): | |||
Females | Plasma | 0.6–3.3 mg/mL | 1.6–8.9 μmol/L |
Males | Plasma | 1.3–5.5 mg/mL | 3.5–14.9 μmol/L |
δ-Aminolevulinic acid (ALA) | Serum | 15–23 μg/L | 1.14–1.75 μmol/L |
| 11-Deoxycortisol (DOC): | |||
After metyrapone
| Plasma | > 7 μg/dL | > 203 nmol/L |
Basal | Plasma | < 5 μg/dL | < 145 nmol/L |
d-Xylose level 2 h after ingestion of 25 g of d-xylose | Serum | > 20 mg/dL | > 1.3 nmol/L |
| Epinephrine, supine | Plasma | < 75 ng/L | < 410 pmol/L |
| Erythrocyte sedimentation rate (ESR): | |||
Females | Blood | 0–20 mm/h | 0–20 mm/h |
Males | Blood | 0–15 mm/h | 0–20 mm/h |
Erythropoietin | Serum | 4.0–18.5 mIU/mL | 4.0–18.5 IU/L |
| Estradiol, females: | |||
Day 1–10 of menstrual cycle | Serum | 14–27 pg/mL | 50–100 pmol/L |
Day 11–20 of menstrual cycle | Serum | 14–54 pg/mL | 50–200 pmol/L |
Day 21–30 of menstrual cycle | Serum | 19–40 pg/mL | 70–150 pmol/L |
| Estradiol, males | Serum | 10–30 pg/mL | 37–110 pmol/L |
Ferritin | Serum | 15–200 ng/mL | 15–200 μg/L |
α-Fetoprotein (AFP) | Serum | 0–20 ng/dL | 0–20 pg/L |
Fibrinogen | Plasma | 150–350 mg/dL | 1.5–3.5 g/L |
| Folate (folic acid): | |||
RBC | Blood | 160–855 ng/mL | 362–1937 nmol/L |
Serum | Serum | 2.5–20 ng/mL | 5.7–45.3 nmol/L |
| Follicle-stimulating hormone (FSH), females: | |||
Follicular or luteal phase | Serum | 5–20 mU/mL | 5–20 U/L |
Midcycle peak | Serum | 30–50 mU/mL | 30–50 U/L |
Postmenopausal | Serum | > 35 mU/mL | > 35 U/L |
Follicle-stimulating hormone (FSH), adult males | Serum | 5–15 mU/mL | 5–15 U/L |
Fructosamine | Plasma | 200–285 mol/L | — |
Gamma-glutamyl transpeptidase (GGT) | Serum | 8–78 U/L | — |
Gastrin | Serum | 0–180 pg/mL | 0–180 ng/L |
Globulins: | Serum | 2.5–3.5 g/dL | 25–35 g/L |
α1-Globulins | Serum | 0.2–0.4 g/dL | 2–4 g/L |
α2-Globulins | Serum | 0.5–0.9 g/dL | 5–9 g/L |
β-Globulins | Serum | 0.6–1.1 g/dL | 6–11 g/L |
γ-Globulins | Serum | 0.7–1.7 g/dL | 7–17 g/L |
β2-Microglobulin | Serum | 0.7–1.8 μg/mL | — |
| Glucose: | |||
2-h postprandial | Plasma | < 140 mg/dL | < 7.8 mmol/L |
Fasting | Plasma | 70–105 mg/dL | 3.9–5.8 mmol/L |
Glucose-6-phosphate dehydrogenase (G6PD) | Blood | 5–15 U/g Hb | 0.32–0.97 mU/ mol Hb |
γ-Glutamyl transpeptidase (GGT) | Serum | 8–78 U/L | — |
| Growth hormone: | |||
After oral glucose | Plasma | < 2 ng/mL | < 2 μg/L |
In response to provocative stimuli | Plasma | > 7 ng/mL | > 7 μg/L |
Haptoglobin | Serum | 30–200 mg/dL | 300–2000 mg/L |
| Hematocrit: | |||
Females | Blood | 36–47% | — |
Males | Blood | 41–51% | — |
| Hemoglobin: | |||
Females | Blood | 12–16 g/dL | 120–160 g/L |
Males | Blood | 14–17 g/dL | 140–170 g/L |
Hemoglobin A1c | Blood | 4.7–8.5% | — |
| Hemoglobin electrophoresis, adults: | |||
Hb A1 | Blood | 95–98% | — |
Hb A2 | Blood | 2–3% | — |
Hb C | Blood | 0% | — |
Hb F | Blood | 0.8–2.0% | — |
Hb S | Blood | 0% | — |
| Hemoglobin electrophoresis, Hb F in children: | |||
Neonate | Blood | 50–80% | — |
1–6 mo | Blood | 8% | — |
> 6 mo | Blood | 1–2% | — |
| Homocysteine: | |||
Females | Plasma | 0.40–1.89 mg/L | 3–14 μmol/L |
Males | Plasma | 0.54–2.16 mg/L | 4–16 μmol/L |
Human chorionic gonadotropin (hCG), quantitative | Serum | < 5 mIU/mL | — |
| Immunoglobulins: | |||
Serum | 70–300 mg/dL | 0.7–3.0 g/L | |
Serum | < 8 mg/dL | < 80 mg/L | |
Serum | 0.01–0.04 mg/dL | 0.1–0.4 mg/L | |
Serum | 640–1430 mg/dL | 6.4–14.3 g/L | |
IgG1 | Serum | 280–1020 mg/dL | 2.8–10.2 g/L |
IgG2 | Serum | 60–790 mg/dL | 0.6–7.9 g/L |
IgG3 | Serum | 14–240 mg/dL | 0.14–2.4 g/L |
IgG4 | Serum | 11–330 mg/dL | 0.11–3.3 g/L |
Serum | 20–140 mg/dL | 0.2–1.4 g/L | |
Insulin, fasting | Serum | 1.4–14 μIU/mL | 10–104 pmol/L |
| International normalized ratio (INR): | |||
Therapeutic range (standard intensity therapy) | Plasma | 2.0–3.0 | — |
Therapeutic range in patients at higher risk (eg, patients with prosthetic heart valves) | Plasma | 2.5–3.5 | — |
Therapeutic range in patients with lupus anticoagulant | Plasma | 3.0–3.5 | — |
Iron | Serum | 60–160 μg/dL | 11–29 μmol/L |
Iron-binding capacity, total (TIBC) | Serum | 250–460 μg/dL | 45–82 μmol/L |
Lactate dehydrogenase (LDH) | Serum | 60–160 U/L | 1–1.67 μkat/L |
Lactic acid, venous | Blood | 6–16 mg/dL | 0.67–1.8 mmol/L |
Lactose tolerance test | Plasma | > 15 mg/dL increase in plasma glucose level | > 0.83 mmol/L increase in plasma glucose level |
Lead | Blood | < 40 μg/dL | < 1.9 μmol/L |
Leukocyte alkaline phosphatase (LAP) score | Peripheral blood smear | 13–130/100/ polymorphonuclear (PMN) leukocyte neutrophils and bands | — |
Lipase | Serum | < 95 U/L | < 1.58 μkat/L |
Lipoprotein (a) [Lp(a)] | Serum | ≤ 30 mg/dL | < 1.1 μmol/L |
| Luteinizing hormone (LH), females: | |||
Follicular or luteal phase | Serum | 5–22 mU/mL | 5–22 U/L |
Midcycle peak | Serum | 30–250 mU/mL | 30–250 U/L |
Postmenopausal | Serum | > 30 mU/mL | > 30 U/L |
Luteinizing hormone, males | Serum | 3–15 mU/mL | 3–15 U/L |
Magnesium | Serum | 1.5–2.4 mg/dL | 0.62–0.99 mmol/L |
Manganese | Serum | 0.3–0.9 ng/mL | 5.5–16.4 nmol/L |
Mean corpuscular hemoglobin (MCH) | Blood | 28–32 pg | — |
Mean corpuscular hemoglobin concentration (MCHC) | Blood | 32–36 g/dL | 320–360 g/L |
Mean corpuscular volume (MCV) | Blood | 80–100 fL | — |
| Metanephrines, fractionated: | |||
Metanephrines, free | Plasma | < 0.50 nmol/L | — |
Normetanephrines, free | Plasma | < 0.90 nmol/L | — |
Methemoglobin | Blood | < 1.0% | — |
Methylmalonic acid (MMA) | Serum | 150–370 nmol/L | — |
Myeloperoxidase (MPO) antibodies | Serum | < 6.0 U/mL | — |
| Myoglobin: | |||
Females | Serum | 25–58 μg/L | 1.4–3.5 nmol/L |
Males | Serum | 28–72 μg/L | 1.6–4.1 nmol/L |
| Norepinephrine, supine | Plasma | 50–440 pg/mL | 0.3–2.6 nmol/L |
N-Terminal propeptide of BNP (NT-proBNP) | Plasma | < 125 pg/mL | — |
5′-Nucleotidase (5’NT) | Serum | 4–11.5 U/L | — |
Osmolality | Plasma | 275–295 mOsm/kg H2O | 275–295 mmol/ kg H2O |
Osmotic fragility test | Blood | Increased fragility if hemolysis occurs in > 0.5% NaCl Decreased fragility if hemolysis is incomplete in 0.3% NaCl | — |
Oxygen partial pressure (PO2) | Blood | 80–100 mm Hg | — |
Parathyroid hormone (PTH) | Serum | 10–65 pg/mL | 10–65 ng/L |
Parathyroid hormone–related peptide (PTHrP) | Plasma | < 2.0 pmol/L | — |
Partial thromboplastin time, activated (aPTT) | Plasma | 25–35 sec | — |
pH | Blood | 7.38–7.44 | — |
Phosphorus, inorganic | Serum | 3.0–4.5 mg/dL | 0.97–1.45 mmol/L |
Platelet count | Blood | 150–350 x 103/μL | 150–350 x 109/L |
Platelet life span, using chromium-51 (51Cr) | — | 8–12 days | — |
Porphyrins | Plasma | ≤ 1.0 μg/dL | — |
Potassium | Serum | 3.5–5 mEq/L | 3.5–5 mmol/L |
Prealbumin (transthyretin) | Serum | 18–45 mg/dL | — |
| Progesterone: | |||
Follicular phase | Serum | < 1 ng/mL | < 0.03 nmol/L |
Luteal phase | Serum | 3–30 ng/mL | 0.1–0.95 nmol/L |
| Prolactin: | |||
Females | Serum | < 20 μg/L | < 870 pmol/L |
Males | Serum | < 15 μg/L | < 652 pmol/L |
Prostate-specific antigen, total (PSA-T) | Serum | 0–4 ng/mL | — |
Prostate-specific antigen, ratio of free to total (PSA-F:PSA-T) | Serum | > 0.25 | — |
Protein C activity | Plasma | 67–131% | — |
Protein C resistance, activated ratio (APC-R) | Plasma | 2.2–2.6 | — |
Protein S activity | Plasma | 82–144% | — |
Protein, total | Serum | 6–7.8 g/dL | 60–78 g/L |
Prothrombin time (PT) | Plasma | 11–13 sec | — |
Pyruvate | Blood | 0.08–0.16 mmol/L | — |
RBC count | Blood | 4.2–5.9 x 106 cells/μL | 4.2–5.9 x 1012cells/L |
RBC survival rate, using 51Cr | Blood | T1/2 = 28 days | — |
| Renin activity, plasma (PRA), upright, in males and females aged 18–39 yr: | |||
Sodium-depleted | Plasma | 2.9–24 ng/mL/h | — |
Sodium-repleted | Plasma | 0.6 (or lower)–4.3 ng/mL/h | — |
| Reticulocyte count: | |||
Percentage | Blood | 0.5–1.5% | — |
Absolute | Blood | 23–90 x 103/μL | 23–90 x 109/L |
Rheumatoid factor (RF) | Serum | < 40 U/mL | < 40 kU/L |
Sodium | Serum | 136–145 mEq/L | 136–145 mmol/L |
| Testosterone, adults: | |||
Females | Serum | 20–75 ng/dL | 0.7–2.6 nmol/L |
Males | Serum | 300–1200 ng/dL | 10–42 nmol/L |
Thrombin time | Plasma | 18.5–24 sec | — |
Thyroid iodine-123 (123I) uptake | — | 5–30% of administered dose at 24 h | — |
Thyroid-stimulating hormone (TSH) | Serum | 0.5–5.0 μIU/mL | 0.5–5.0 mIU/L |
| Thyroxine (T4): | |||
Free | Serum | 0.9–2.4 ng/dL | 12–31 pmol/L |
Free index | — | 4–11 μg/dL | — |
Total | Serum | 5–12 μg/dL | 64–155 nmol/L |
Transferrin | Serum | 212–360 mg/dL | 2.1–3.6 g/L |
Transferrin saturation | Serum | 20–50% | — |
Triglycerides (desirable level) | Serum | < 250 mg/dL | < 2.82 mmol/L |
| Triiodothyronine (T3): | |||
Uptake | Serum | 25–35% | — |
Total | Serum | 70–195 ng/dL | 1.1–3.0 nmol/L |
Troponin I | Plasma | < 0.1 ng/mL | < 0.1 μg/L |
Troponin T | Serum | ≤ 0.03 ng/mL | ≤ 0.03 μg/L |
Urea nitrogen (BUN) | Serum | 8–20 mg/dL | 2.9–7.1 mmol/L |
Uric acid | Serum | 2.5–8 mg/dL | 0.15–0.47 mmol/L |
Vitamin B12 | Serum | 200–800 pg/mL | 148–590 pmol/L |
| Vitamin C (ascorbic acid): | |||
Leukocyte | Blood | < 20 mg/dL | < 1136 μmol/L |
Total | Blood | 0.4–1.5 mg/dL | 23–85 μmol/L |
| Vitamin D: | |||
1,25-Dihydroxycholecalciferol (calcitriol)
| Serum | 25–65 pg/mL | 65–169 pmol/L |
25-Hydroxycholecalciferol | Serum | 15–80 ng/mL | 37–200 nmol/L |
WBC count | Blood | 3.9–10.7 x 103 cells/μL | 3.9–10.7 x 109cells/L |
Zinc | Serum | 66–110 μg/dL | 10.1–16.8 μmol/L |
μkat = microkatal; pkat = picokatal.
Normal Laboratory Values: Urine
| Test | Specimen | Conventional Units | SI Units |
|---|---|---|---|
Aldosterone | Urine, 24 h | 5–19 μg/24 h | 13.9–52.6 nmol/24 h |
Amino acids, total | Urine, 24 h | 200–400 mg/24 h | 14–29 nmol/24 h |
Amylase | Urine, timed | 6.5–48.1 U/h | — |
Calcium, with patients on an unrestricted diet | Urine, timed | 100–300 mg/day | 2.5–7.5 mmol/day |
Catecholamines, total | Urine, 24 h | < 100 μg/m2/24 h | < 591 nmol/m2/24 h |
Chloride | Urine, timed | 80–250 mEq/day | 80–250 mmol/day |
Copper | Urine, 24 h | 0–100 μg/24 h | 0–1.6 μmol/24 h |
Coproporphyrin | Urine, 24 h | 50–250 μg/24 h | 76–382 nmol/24 h |
Cortisol, free | Urine, 24 h | < 90 μg/24 h | < 248 nmol/24 h |
Creatine: | |||
Females | Urine, 24 h | 0–100 mg/24 h | 0–763 mmol/24 h |
Males | Urine, 24 h | 4–40 mg/24 h | 30–305 mmol/24 h |
Creatinine, weight-based | Urine, 24 h | 15–25 mg/kg/24 h | 133–221 mmol/kg/ 24 h |
| d-Xylose excretion 5 h after ingestion of 25 g of d-xylose | Urine, 5 h collection | 5–8 g | 33–53 mmol |
Estriol, females | Urine, 24 h | > 12 mg/24 h | > 42 μmol/24 h |
17-Hydroxycorticosteroids, fractionated, adults ≥ 18 yr: | |||
Cortisol | Urine, 24 h | 3.5–4.5 μg/24 h | 9.7–12.4 nmol/24 h |
Cortisone | Urine, 24 h | 17–129 μg/24 h | 47–359 nmol/24 h |
5-Hydroxyindoleacetic acid (5-HIAA) | Urine, 24 h | 2–9 mg/24 h | 10.4–46.8 μmol/24 h |
17-Ketosteroid, fractionated, females > 12 yr: | |||
Androsterone | Urine, 24 h | 55–1589 μg/24 h | — |
Pregnanetriol | Urine, 24 h | 59–1391 μg/24 h | — |
17-Ketosteroid, fractionated, males > 12 yr: | |||
Androsterone | Urine, 24 h | 234–2703 μg/24 h | — |
Etiocholanolone | Urine, 24 h | 151–3198 μg/24 h | — |
11-Hydroxyandrosterone | Urine, 24 h | 66–1032 μg/24 h | — |
11-Hydroxyetiocholanolone | Urine, 24 h | 17–1006 μg/24 h | — |
11-Ketoandrosterone | Urine, 24 h | 4–55 μg/24 h | — |
11-Ketoetiocholanolone | Urine, 24 h | 51–1016 μg/24 h | — |
Pregnanetriol | Urine, 24 h | 245–1701 μg/24 h | — |
Metanephrines, fractionated, normotensive patients ≥ 18 yr: | |||
Females, metanephrine | Urine, 24 h | 30–180 μg/24 h | — |
Females, total metanephrines | Urine, 24 h | 142–510 μg/24 h | — |
Males, metanephrine | Urine, 24 h | 44–261 μg/24 h | — |
Males, total metanephrines | Urine, 24 h | 190–583 μg/24 h | — |
Metanephrines, fractionated, normotensive males and females aged 18–29 yr: | |||
Normetanephrine | Urine, 24 h | 103–390 μg/24 h | — |
Metanephrines, fractionated, hypertensive males and females: | |||
Metanephrine | Urine, 24 h | < 400 μg/24 h | — |
Normetanephrine | Urine, 24 h | < 900 μg/24 h | — |
Total metanephrines | Urine, 24 h | < 1300 μg/24 h | — |
Microalbumin | Urine, 24 h | < 30 mg/24 h | — |
Microalbumin, albumin/ creatinine ratio | Urine, random | < 20 μg/mg | — |
Osmolality | Urine, random | 38–1400 mOsm/kg H2O | — |
Oxalate | Urine, 24 h | 0.11–0.46 mmol/ specimen* | — |
Phosphate, tubular reabsorption | Urine, random | 79–94% of filtered load | — |
Porphobilinogens | Urine, random | 0–0.5 mg/g creatinine | — |
Potassium | Urine, 24 h | 25–100 mEq/24 h | 25–100 mmol/24 h |
Protein, total | Urine, 24 h | < 100 mg/24 h | — |
Sodium | Urine, 24 h | 100–260 mEq/24 h | 100–260 mmol/24 h |
Uric acid | Urine, 24 h | 250–750 mg/24 h | 1.48–4.43 mmol/24 h |
Urinalysis, routine† | |||
pH | Urine, random | 5–7 | — |
Urinalysis, routine, dipstick testing†: | |||
Bilirubin | Urine, random | Negative | — |
Blood | Urine, random | Negative | — |
Glucose | Urine, random | Negative | — |
Ketones | Urine, random | Negative | — |
Leukocyte esterase | Urine, random | Negative | — |
Nitrites | Urine, random | Negative | — |
Protein | Urine, random | Negative | — |
Urobilinogen | Urine, random | 0.2–1.0 EU | — |
Urobilinogen | Urine, 24 h | 0.05–2.5 mg/24 h | 0.08–4.22 μmol/24 h |
Vanillylmandelic acid (VMA) | Urine, 24 h | < 8 mg/24 h | < 40.4 mol/24 h |
*Value is based on 24-h collection.†Normal findings detected by microscopic examination can include a few RBCs (especially in menstruating women), WBCs, epithelial cells, bacteria, yeast cells, crystals (eg, Ca oxalate, triple phosphate, amorphous phosphates and urates), sperm, and unidentifiable materials. Large amounts of these substances or the presence of certain other materials may be abnormal.
EU = Ehrlich units.
Normal Laboratory Values: CSF
| Test | Conventional Units | SI Units |
|---|---|---|
Cell count | 0–5 cells/μL | 0–0.5 x 106 cells/L |
Glucose | 40–80 mg/dL (< 40% of simultaneously measured plasma level if that plasma level is abnormal) | 2.5–4.4 mmol/L (< 40% of simultaneously measured plasma level is abnormal) |
Myelin basic protein | < 1.5 ng/mL | — |
Protein, total | 15–60 mg/dL | 150–600 mg/L |
Normal Laboratory Values: Stool
| Test | Conventional Units | SI Units |
|---|---|---|
Fat | < 5 g/day in patients on a 100-g fat diet | — |
Nitrogen | < 2 g/day | — |
Urobilinogen | 40–280 mg/24 h | 68–473 mg/24 h |
Weight | < 200 g/day | — |
Source: The Merck Manual
Dear Sagar
Thank you for your interesting posts. Don’t you think the term “normal value” is better to change with “Reference Interval” as explained in CLSI and ISO terminology?
Sagar,
This is very impressive and shows passion for the profession on your side. What a commendable effort to make such a compilation for sharing. However may I know if a global geographical distribution difference was calculated as it has proved in my over 35 years of service in the field that blood value (normal) range from caucasian communities are not the same with the Afro-comminities. All the same your effort,once again,is very commendable.